menu toggle

White paper: Navigating new U.S. serialization requirements for pharmaceutical logistics success

By ICS Connect


Enacted in 2013, the Drug Quality and Security Act (DQSA) introduced serialization requirements for drug products to enable effective traceability, with ramifications for pharmaceutical companies’ logistics needs when operating in the U.S.

With the deadline for phase 2 on the rapidly-approaching horizon, fresh challenges emerge for every organization along the pharmaceutical and biotech supply chain — not just manufacturers, but third-party logistics (3PL) providers, wholesalers, and dispensers, too.

How can companies ensure that they have the right supply chain solution to meet future track and trace compliance needs? Access this insightful white paper now to better understand the ‘what’ and ‘why’ of these changes, and ultimately how to ensure total supply chain compliancy.

What can be gained from this white paper?

  • An in-depth understanding of the provisions of the new FDA requirements and the reasons for the new legislation.
  • Awareness of the benefits that can be gained from these new requirements not just for pharmaceutical companies’ brand reputation, but ultimately for patient safety.
  • Knowledge of the steps as to how pharmaceutical companies can ensure they remain compliant with changing U.S. requirements.